KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.

ABSTRACT:

Background

Predictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information.

Methods

The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic alterations. Additionally, two previously published immunotherapy and two surgical patient cohorts were analyzed. Therapy benefit was stratified by KRAS and TP53 mutations. Molecular characteristics underlying KRASmut/TP53mut tumours were revealed by the analysis of TCGA data.

Results

An interaction between KRAS and TP53 mutations was observed in univariate and multivariat

SUBMITTER: Budczies J 

PROVIDER: S-EPMC11300455 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature